S&P 500   4,283.10 (+0.37%)
DOW   33,796.31 (+0.39%)
QQQ   351.54 (+0.78%)
AAPL   179.40 (+0.89%)
MSFT   323.77 (+0.12%)
META   265.38 (+0.68%)
GOOGL   121.87 (-0.51%)
AMZN   123.86 (+2.17%)
TSLA   231.22 (+2.96%)
NVDA   382.90 (+2.17%)
NIO   7.71 (-0.64%)
BABA   86.34 (+1.24%)
AMD   119.99 (+1.83%)
T   16.00 (-0.62%)
F   13.53 (-0.44%)
MU   64.73 (-3.47%)
CGC   0.70 (-2.77%)
GE   106.73 (+0.61%)
DIS   92.38 (-0.15%)
AMC   4.63 (-2.11%)
PFE   39.18 (+0.75%)
PYPL   64.00 (-0.06%)
NFLX   402.58 (+0.70%)
S&P 500   4,283.10 (+0.37%)
DOW   33,796.31 (+0.39%)
QQQ   351.54 (+0.78%)
AAPL   179.40 (+0.89%)
MSFT   323.77 (+0.12%)
META   265.38 (+0.68%)
GOOGL   121.87 (-0.51%)
AMZN   123.86 (+2.17%)
TSLA   231.22 (+2.96%)
NVDA   382.90 (+2.17%)
NIO   7.71 (-0.64%)
BABA   86.34 (+1.24%)
AMD   119.99 (+1.83%)
T   16.00 (-0.62%)
F   13.53 (-0.44%)
MU   64.73 (-3.47%)
CGC   0.70 (-2.77%)
GE   106.73 (+0.61%)
DIS   92.38 (-0.15%)
AMC   4.63 (-2.11%)
PFE   39.18 (+0.75%)
PYPL   64.00 (-0.06%)
NFLX   402.58 (+0.70%)
S&P 500   4,283.10 (+0.37%)
DOW   33,796.31 (+0.39%)
QQQ   351.54 (+0.78%)
AAPL   179.40 (+0.89%)
MSFT   323.77 (+0.12%)
META   265.38 (+0.68%)
GOOGL   121.87 (-0.51%)
AMZN   123.86 (+2.17%)
TSLA   231.22 (+2.96%)
NVDA   382.90 (+2.17%)
NIO   7.71 (-0.64%)
BABA   86.34 (+1.24%)
AMD   119.99 (+1.83%)
T   16.00 (-0.62%)
F   13.53 (-0.44%)
MU   64.73 (-3.47%)
CGC   0.70 (-2.77%)
GE   106.73 (+0.61%)
DIS   92.38 (-0.15%)
AMC   4.63 (-2.11%)
PFE   39.18 (+0.75%)
PYPL   64.00 (-0.06%)
NFLX   402.58 (+0.70%)
S&P 500   4,283.10 (+0.37%)
DOW   33,796.31 (+0.39%)
QQQ   351.54 (+0.78%)
AAPL   179.40 (+0.89%)
MSFT   323.77 (+0.12%)
META   265.38 (+0.68%)
GOOGL   121.87 (-0.51%)
AMZN   123.86 (+2.17%)
TSLA   231.22 (+2.96%)
NVDA   382.90 (+2.17%)
NIO   7.71 (-0.64%)
BABA   86.34 (+1.24%)
AMD   119.99 (+1.83%)
T   16.00 (-0.62%)
F   13.53 (-0.44%)
MU   64.73 (-3.47%)
CGC   0.70 (-2.77%)
GE   106.73 (+0.61%)
DIS   92.38 (-0.15%)
AMC   4.63 (-2.11%)
PFE   39.18 (+0.75%)
PYPL   64.00 (-0.06%)
NFLX   402.58 (+0.70%)
OTCMKTS:ZLDPF

Zealand Pharma A/S (ZLDPF) Stock Forecast, Price & News

$38.25
0.00 (0.00%)
(As of 06/7/2023 ET)
Compare
Today's Range
$38.25
▼
$38.25
50-Day Range
$30.38
▼
$41.75
52-Week Range
$11.83
▼
$41.75
Volume
N/A
Average Volume
399 shs
Market Capitalization
$1.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort Interest

ZLDPF stock logo

About Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Receive ZLDPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ZLDPF Stock News Headlines

June 6, 2023 | finance.yahoo.com
Recent Price Trend in Zealand Pharma A/S (ZLDPF) is Your Friend, Here's Why
June 6, 2023 | finance.yahoo.com
Zealand Pharma to Participate in Upcoming Healthcare Conferences
June 8, 2023 | Edge On The Street (Ad)
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
May 31, 2023 | finance.yahoo.com
Total number of shares and voting rights in Zealand Pharma at May 31, 2023
May 29, 2023 | americanbankingnews.com
Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Significant Drop in Short Interest
May 11, 2023 | finance.yahoo.com
Zealand Pharma Announces Financial Results for the First Quarter of 2023
May 10, 2023 | benzinga.com
Obesity Drug Achieves ~15% Weight Loss - Zealand Pharma-Boehringer Ingelheim Partnered Drug May Compete With Novo Nordisk, Eli Lilly
May 10, 2023 | msn.com
Boehringer, Zealand's drug helps cut weight up to 14.9%, meets phase 2 trial's goal
June 8, 2023 | Edge On The Street (Ad)
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
May 10, 2023 | finance.yahoo.com
UPDATE 2-Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial
May 10, 2023 | finance.yahoo.com
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
May 4, 2023 | finance.yahoo.com
Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results
April 28, 2023 | finance.yahoo.com
Total number of shares and voting rights in Zealand Pharma at April 28, 2023
April 3, 2023 | finance.yahoo.com
Zealand Pharma A/S publishes a listing prospectus regarding admission to trading and official listing of 6,578,948 new shares on Nasdaq Copenhagen
April 2, 2023 | americanbankingnews.com
Contrasting Zealand Pharma A/S (OTCMKTS:ZLDPF) & Melco International Development (OTCMKTS:MDEVF)
March 31, 2023 | finance.yahoo.com
Total number of shares and voting rights in Zealand Pharma at March 31, 2023
March 30, 2023 | finance.yahoo.com
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion
March 30, 2023 | americanbankingnews.com
Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Increase in Short Interest
March 16, 2023 | reuters.com
New Zealand's Fonterra posts 50% jump in half-year profit
March 15, 2023 | money.usnews.com
New Zealand Fourth-Quarter GDP Below Expectations as It Falls 0.6%
March 3, 2023 | finance.yahoo.com
Correction: Zealand Pharma convenes its Annual General Meeting 2023
February 27, 2023 | msn.com
New Zealand set England 258 to win second Test after Williamson century
February 24, 2023 | yahoo.com
The Ultimate New Zealand Packing List
February 24, 2023 | finance.yahoo.com
Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022
February 18, 2023 | msn.com
Broad fires England to verge of first Test win over New Zealand
February 18, 2023 | msn.com
Watch: New Zealand troops supply aid to storm-hit towns
February 12, 2023 | cnn.com
Schools to close, flights canceled as New Zealand’s largest city braces for Cyclone Gabrielle
See More Headlines

ZLDPF Price History

ZLDPF Company Calendar

Last Earnings
5/11/2023
Today
6/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ZLDPF
Previous Symbol
NASDAQ:ZLDPF
CUSIP
N/A
CIK
N/A
Web
www.zealandpharma.com
Phone
45-8877-3600
Fax
45-8877-3898
Employees
355
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-170,220,000.00
Net Margins
-1,140.99%
Pretax Margin
-972.87%
Return on Equity
-164.35%
Return on Assets
-74.39%

Debt

Debt-to-Equity Ratio
0.58
Current Ratio
7.53
Quick Ratio
7.47

Sales & Book Value

Annual Sales
$14.73 million
Price / Sales
133.76
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.24 per share
Price / Book
17.08

Miscellaneous

Outstanding Shares
51,510,000
Free Float
N/A
Market Cap
$1.97 billion
Optionable
Not Optionable
Beta
0.68

Key Executives

  • Mr. Adam Sinding Steensberg M.D. (Age 49)
    Pres & CEO
    Comp: $733.86k
  • Ms. Henriette Wennicke
    Chief Financial Officer
  • Mr. Ivan Mourits Moller (Age 51)
    Chief Operating Officer
  • Lani Pollworth Morvan
    Investor Relations & Communications Officer
  • Mr. Mads Kronborg
    Head of Investor Relations & Communication
  • Mr. Ravinder Chahil
    Sr. VP & Gen. Counsel
  • Ms. Christina Sonnenborg Bredal (Age 38)
    Sr. VP and Global Head of People & Organization
  • Ms. Hanne Heidenheim Bak (Age 70)
    Sr. Project Director, R&D Operations Mang. and Employee Representative Director
  • Dr. Jens Damsgaard Mikkelsen M.D.
    Head of Molecular Pharmacology
  • Dr. Danilo Verge
    Head of Global Medical Affairs

Key Competitors

View All Competitors













ZLDPF Stock - Frequently Asked Questions

Should I buy or sell Zealand Pharma A/S stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZLDPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZLDPF, but not buy additional shares or sell existing shares.
View ZLDPF analyst ratings or view top-rated stocks.

How have ZLDPF shares performed in 2023?

Zealand Pharma A/S's stock was trading at $28.18 on January 1st, 2023. Since then, ZLDPF shares have increased by 35.7% and is now trading at $38.25.
View the best growth stocks for 2023 here.

Are investors shorting Zealand Pharma A/S?

Zealand Pharma A/S saw a decrease in short interest in May. As of May 15th, there was short interest totaling 671,300 shares, a decrease of 20.7% from the April 30th total of 847,000 shares. Based on an average trading volume of 1,200 shares, the days-to-cover ratio is currently 559.4 days.
View Zealand Pharma A/S's Short Interest.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (OTCMKTS:ZLDPF) released its quarterly earnings data on Thursday, May, 11th. The company reported ($0.54) earnings per share (EPS) for the quarter. The company had revenue of $1.96 million for the quarter. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 164.35% and a negative net margin of 1,140.99%.

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the OTCMKTS under the ticker symbol "ZLDPF."

How do I buy shares of Zealand Pharma A/S?

Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zealand Pharma A/S's stock price today?

One share of ZLDPF stock can currently be purchased for approximately $38.25.

How much money does Zealand Pharma A/S make?

Zealand Pharma A/S (OTCMKTS:ZLDPF) has a market capitalization of $1.97 billion and generates $14.73 million in revenue each year.

How many employees does Zealand Pharma A/S have?

The company employs 355 workers across the globe.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is Sydmarken 11 Soborg, Copenhagen G7, 2860. The official website for the company is www.zealandpharma.com. The company can be reached via phone at 45-8877-3600, via email at investors@zealandpharma.com, or via fax at 45-8877-3898.

This page (OTCMKTS:ZLDPF) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -